Skip to main content
. Author manuscript; available in PMC: 2011 Feb 28.
Published in final edited form as: Ann Neurol. 2009 Jan;65(1):67–75. doi: 10.1002/ana.21536

Fig 3.

Fig 3

Therapeutic effect of C5 complement inhibitor (rEV576) in actively induced experimentally acquired myasthenia gravis (EAMG). Depending on weight loss and grip strength, we randomly divided rats into two groups. Subsequently, rats were treated intraperitoneally with C5 complement inhibitor or phosphate-buffered saline (see Materials and Methods). Inhibition of complement prevented weight loss in severe EAMG (S-EAMG). Results from one representative experiment are shown as ± standard error of the mean for each of three experimental groups. Black circles represent S-EAMG group (n = 9); dark gray squares represent S-EAMG + rEV576 group (n = 7); light gray triangles represent not immunized group (n = 6).